Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Prostatic Neoplasms 1Peripheral Nervous System Diseases 1Nasopharyngeal Carcinoma 1Lymphoma, Non-Hodgkin 1Gastroesophageal Adenocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 243Carboplatin 211Pemetrexed 177Cisplatin 131Paclitaxel 113Nivolumab 101Docetaxel 87osimertinib 85durvalumab 78Specimen Handling 56atezolizumab 55Gemcitabine 52Drug Therapy 52Magnetic Resonance Spectroscopy 50Radiosurgery 48Radiotherapy 47Ipilimumab 41130-nm albumin-bound paclitaxel 39cemiplimab 38Bevacizumab 34Cetuximab 30tislelizumab 29amivantamab 22Taxes 22Platinum Compounds 20Blood Specimen Collection 20Immunotherapy 18Immune Checkpoint Inhibitors 18Radiation 17Erlotinib Hydrochloride 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × Single Person × 1 year × Clear all
NCT04585477 2026-02-10

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Stanford University

Phase 2 Recruiting
80 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡